-
公开(公告)号：US20140080155A1
公开(公告)日：2014-03-20
申请号：US14088638
申请日：2013-11-25
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52
摘要： Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
摘要翻译： 通过随时间检测流体样品中嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的量来评估患有慢性肾功能衰竭（CRF）的受试者正在进行的肾脏状态的方法。 NGAL是一种小分泌的多肽，其是蛋白酶抗性的，因此由于慢性肾小管细胞损伤在尿液和血清中容易检测到。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于CRF恶化的其他指标，如增加血清肌酐，增加尿蛋白分泌，降低肾小球滤过率（GFR）。 正确检测恶化（或改善，如果治疗已经建立）肾脏状态随着时间的推移，由患者治疗前和治疗后的NGAL水平证实，可以帮助设计和/或维持适当的治疗方案以减慢或停止 CRF进展。
-
公开(公告)号：US20130137122A1
公开(公告)日：2013-05-30
申请号：US13747646
申请日：2013-01-23
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/50 , G01N2800/56
摘要： A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
-
3.发明申请公开(公告)号：US20100254970A1
公开(公告)日：2010-10-07
申请号：US12817566
申请日：2010-06-17
CPC分类号： G01N33/6893 , A01N1/0226 , A61K38/1709 , A61K39/025 , G01N33/74 , G01N2333/47 , G01N2800/347 , A61K2300/00
摘要： Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
摘要翻译： 使用嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为治疗剂，以及将治疗，减少或改善选自缺血性损伤，缺血再灌注损伤和毒素诱导的损伤的损伤的方法应用于 患者。 本发明包括以有效治疗，减轻或改善对器官（例如肾）的缺血性，缺血再灌注或毒素诱导的损伤的量向患者NGAL施用。 铁载体可与NGAL共同施用。 本发明还涉及在对患者的器官的缺血或毒素诱导的损伤之后施用形象以增强对NGAL分泌的反应。
-
4.发明授权公开(公告)号：US07776824B2
公开(公告)日：2010-08-17
申请号：US11123364
申请日：2005-05-06
CPC分类号： G01N33/6893 , A01N1/0226 , A61K38/1709 , A61K39/025 , G01N33/74 , G01N2333/47 , G01N2800/347 , A61K2300/00
摘要： Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
摘要翻译： 使用嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为治疗剂，以及将治疗，减少或改善选自缺血性损伤，缺血再灌注损伤和毒素诱导的损伤的损伤的方法应用于 患者。 本发明包括以有效治疗，减轻或改善对器官（例如肾）的缺血性，缺血再灌注或毒素诱导的损伤的量向患者NGAL施用。 铁载体可与NGAL共同施用。 本发明还涉及在对患者的器官的缺血或毒素诱导的损伤之后施用形象以增强对NGAL分泌的反应。
-
5.发明授权公开(公告)号：US08247376B2
公开(公告)日：2012-08-21
申请号：US12817566
申请日：2010-06-17
CPC分类号： G01N33/6893 , A01N1/0226 , A61K38/1709 , A61K39/025 , G01N33/74 , G01N2333/47 , G01N2800/347 , A61K2300/00
摘要： Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
摘要翻译： 使用嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为治疗剂，以及将治疗，减少或改善选自缺血性损伤，缺血再灌注损伤和毒素诱导的损伤的损伤的方法应用于 患者。 本发明包括以有效治疗，减轻或改善对器官（例如肾）的缺血性，缺血再灌注或毒素诱导的损伤的量向患者NGAL施用。 铁载体可与NGAL共同施用。 本发明还涉及在对患者的器官的缺血或毒素诱导的损伤之后施用形象以增强对NGAL分泌的反应。
-
公开(公告)号：US20100184089A1
公开(公告)日：2010-07-22
申请号：US12750241
申请日：2010-03-30
IPC分类号： G01N33/573 , G01N33/566
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/50 , G01N2800/56
摘要： A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
-
公开(公告)号：US20080090304A1
公开(公告)日：2008-04-17
申请号：US11770245
申请日：2007-06-28
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/50 , G01N2800/56
摘要： A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
-
公开(公告)号：US20070037232A1
公开(公告)日：2007-02-15
申请号：US11374285
申请日：2005-10-13
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52
摘要： Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
摘要翻译： 公开了通过随时间检测流体样品中嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的量来评估患有慢性肾功能衰竭（CRF）的受试者正在进行的肾脏状态的方法。 NGAL是一种小分泌的多肽，其是蛋白酶抗性的，因此由于慢性肾小管细胞损伤在尿液和血清中容易检测到。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于CRF恶化的其他指标，如增加血清肌酐，增加尿蛋白分泌，降低肾小球滤过率（GFR）。 通过患者治疗前和治疗后的NGAL水平证实，正确检测恶化（或改善，如果治疗已经建立）肾脏状态，可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。
-
公开(公告)号：US20100015648A1
公开(公告)日：2010-01-21
申请号：US12567860
申请日：2009-09-28
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52
摘要： Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
摘要翻译： 公开了通过随时间检测流体样品中嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的量来评估患有慢性肾功能衰竭（CRF）的受试者正在进行的肾脏状态的方法。 NGAL是一种小分泌的多肽，其是蛋白酶抗性的，因此由于慢性肾小管细胞损伤在尿液和血清中容易检测到。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于CRF恶化的其他指标，如增加血清肌酐，增加尿蛋白分泌，降低肾小球滤过率（GFR）。 通过患者治疗前和治疗后的NGAL水平证实，正确检测恶化（或改善，如果治疗已经建立）肾脏状态，可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。
-
公开(公告)号：US20080014644A1
公开(公告)日：2008-01-17
申请号：US11770214
申请日：2007-06-28
IPC分类号： G01N33/48
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52
摘要： A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
摘要翻译： 通过检测尿液，血清或血浆中的嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的量来评估患有慢性肾损伤或疾病的哺乳动物的正在进行的肾脏状态的方法，包括慢性肾功能衰竭（CRF） 样品在离散的时间段，以及随着时间的推移。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于慢性肾病或CRF恶化的其他指标，如血清肌酐升高，尿蛋白分泌增加，肾小球滤过率（GFR）降低。 通过患者治疗前和治疗后的NGAL水平证实，正确检测恶化（或改善，如果治疗已经建立）肾脏状态，可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。
-
-
-
-
-
-
-
-
-
搜索结果
78 条记录 (耗时 0.031 秒)
